1. Home
  2. TVTX vs KVYO Comparison

TVTX vs KVYO Comparison

Compare TVTX & KVYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$51.58

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Logo Klaviyo Inc. Series A

KVYO

Klaviyo Inc. Series A

SELL

Current Price

$17.58

Market Cap

5.3B

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
TVTX
KVYO
Founded
N/A
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
5.3B
IPO Year
2013
2023

Fundamental Metrics

Financial Performance
Metric
TVTX
KVYO
Price
$51.58
$17.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
23
Target Price
★ $75.21
$26.57
AVG Volume (30 Days)
1.6M
★ 5.4M
Earning Date
10-29-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 92.89
35.29
EPS
N/A
★ N/A
Revenue
N/A
★ $1,234,019,000.00
Revenue This Year
$47.65
$24.07
Revenue Next Year
$49.39
$19.57
P/E Ratio
★ N/A
$657.67
Revenue Growth
N/A
★ 31.63
52 Week Low
$22.59
$12.53
52 Week High
$68.73
$33.36

Technical Indicators

Market Signals
Indicator
TVTX
KVYO
Relative Strength Index (RSI) 29.63 56.38
Support Level $41.75 $17.42
Resistance Level $59.93 $18.54
Average True Range (ATR) 2.20 0.78
MACD -0.38 0.23
Stochastic Oscillator 1.49 85.95

Price Performance

Historical Comparison
TVTX
KVYO

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

About KVYO Klaviyo Inc. Series A

Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.

Share on Social Networks: